 ChemoCentryx Inc. NASDAQ: CCXI shares traded higher Tuesday after the company announced it filed an amendment to its New Drug Application for avacopan for the treatment of anti-neutrophil cytoplasmic yutoantibody associated vasculitis. The U.S. Food and Drug Administration FDA filing was set to have a goal date of Oct. 7, 2021. 